Good point, the UP/UC market is much larger and continuing to grow. The problem in my mind is a perception issue though. It's just so much 'sexier' to average investors to put money into a company that has a drug to cure anything related to cancer, as opposed to a drug for rectum and colon issues. While UP/UC are very impacting to those who deal with the illnesses the general public doesn't like to talk or think about issues in that area of the body. I dont know why, but that is the way it is. Therefore, I think it will be easier to get retail investors more excited about B-OM rather than B-UP.

Of course that all really doesn't matter to a savvy big pharma partner who understands the reality of the market size differential for the indications, and nor should it.